Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate

0
40



Takeda Pharmaceutical Firm Restricted (TSE:4502/NYSE:TAK) (“Takeda”) at this time introduced that the corporate is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being carried out after discussions with the FDA and is effec



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here